CIRM Funded Clinical Trials

Phase 2 Safety and Efficacy Study of CLBS03 Autologous T-Regulatory Cells in Adolescents with Recent Onset Type 1 Diabetes Mellitus


Douglas Losordo
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$12,211,255
Trial Sponsor:
Trial Stage: 
Phase 2
Trial Status: 
Recruiting
Targeted Enrollment:
111
ClinicalTrials.gov ID:
Details: 

Children with type 1 diabetes (T1D) face lifelong struggles with glycemic control and, despite careful management, an increased risk of severe complications. No therapy that maintains or restores pancreatic beta islet cell function is currently approved. Evidence indicates that regulatory T-cells (T-regs) maintain immune balance at least in part by control of differentiation of multipotent progenitor/stem cells.

Design: 

Prospective, randomized, double-blinded, placebo-controlled, proof-of-concept study.

Goal: 

Primary: Safety. Secondary: Efficacy.

Status: 

Enrolling; Fast track and Orphan designations.